Blenrep (belantamab mafodotin-blmf) / GSK, Pfizer - LARVOL DELTA

Evaluation of a Vision-Related Anamnestic Tool (VRAT) to Guide Belantamab Mafodotin Dosing With Bortezomib and Dexamethasone for Multiple Myeloma: Interim Results From the UKMRA ProMMise D Trial (IMS 2026) - "The symptom based VRAT approach demonstrated a low rate of false negative results demonstrating its potential to detect significant ocular AEs. Belamaf at Q8W dosing resulted in a low rate of G3-4 ocular events, leading to few dose delays and reductions. Funding: GSK: funding and Belamaf supply."

Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Ophthalmology • Thrombocytopenia

Shifting Landscapes in Triple-Class Exposed Multiple Myeloma in Latin America (LATAM): Real-World Outcomes with Bispecific Antibodies Versus Standard of Care (IMS 2026) - "Pts receiving BsAbs (teclistamab, talquetamab, or elranatamab) were compared with those treated with standard-of-care (SoC)-based salvage regimens. Belantamab mafodotin-treated pts were excluded from the primary comparative analysis due to limited sample size and retained for descriptive purposes only. SoC regimens were grouped as carfilzomib-based, pomalidomide-based, carfilzomib plus pomalidomide-based, chemotherapy-based, and other regimens... In this large real-world LATAM cohort of TCE-RRMM pts, BsAbs were associated with significantly improved response rates and survival outcomes compared with SoC, despite a population enriched with higher refractory burden and EMD prevalence. These findings support the effectiveness of BsAbs in routine clinical practice across LATAM and reinforce the importance of expanding access to novel immunotherapeutic strategies in the region."

Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Selinexor, Mezigdomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Relapsing / Ineligible for T-Cell-Redirecting Therapy (TCRT): STOMP Phase 1 Preliminary Results (IMS 2026) - P1/2 | "Three pts relapsed after TCRT (3 cilta-cel; 2 talquetamab; 1 IGM-2644) and 4 after belantamab mafodotin, with 3 pts refractory to B-cell maturation antigen–targeted therapy. For the SMd all-oral combination, TEAEs were consistent with AE profiles for S and M, and no new safety signals were detected. The DLT of G4 neutropenia was manageable with filgrastim and dose reduction. Across all dose levels SMd showed efficacy in pts with heavily pretreated RRMM in whom TCRT had failed or who could not receive TCRT."

Clinical • IO biomarker • P1 data • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukopenia • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • CCR7 • CRBN • TIGIT • XPO1

Selinexor Treatment Upregulates BCMA and Increases Belamaf Sensitivity in Bcma-Low Cell Line Models (IMS 2026) - "Introduction: Selinexor (Seli), an exportin 1 inhibitor, is approved in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma (MM). Our findings demonstrate that Seli induces a robust upregulation of BCMA receptor density in MM cell models, as quantified by d STORM and supported by increased BCMA gene expression. This enhanced surface expression was associated with increased sensitivity to Belamaf in AMO1 cells, suggesting that Seli may be especially effective as a sensitizing agent in BCMA-low contexts."

IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • XPO1

Role of BCMA Modulation in the Effect of Belantamab Mafodotin in Multiple Myeloma (IMS 2026) - "We here show how modulating BCMA influences BLMF effect. Increasing BCMA expression in MM plasma cells potentiates BLMF effect through an increased binding and internalization. On the other hand, the presence of the microenvironment and continuous exposure to BLMF significantly downregulate BCMA expression, limiting BLMF efficacy."

IO biomarker • Hematological Malignancies • Monoclonal Gammopathy • Multiple Myeloma • Plasmacytoma • ANXA5

Real-World Outcomes Following Second Line Treatment for Multiple Myeloma in Wales (IMS 2026) - "We categorised patients into six groups according to the second line regimen received: Daratumumab, Bortezomib and Dexamethasone (DVd), Carfilzomib, Lenalidomide and Dexamethasone (KRd), Ixazomib, Lenalidomide and Dexamethasone (IRd), Autologous stem cell transplant (Auto), Lenalidomide and Dexamethasone (Rd) and other Proteasome Inhibitor (PI)-based therapies (Other)...In 2025, the UK approved the anti-BCMA, antibody drug conjugate Belantamab Mafodotin, in combination with both Bortezomib and Dexamethasone (BVd) and Pomalidomide and Dexamethasone (BPd) for use at second line. In this real-world analysis of prescribing practice in Wales, our data shows that patients treated with DVd at second line achieved a superior 12mPFS, when compared to other triplet therapies. It also demonstrated an excellent 12mPFS for patients receiving an autologous stem cell transplant at second line. The data confirms the superior outcomes seen in patients with ISS I+II disease at diagnosis;..."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Real Life Data of Belantamab Mafodotin for Patients with Early Relapsed Multiple Myeloma (IMS 2026) - "Introduction: Belantamab mafodotin (BELA) was recently approved for patients with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line, in combination with bortezomib (BOR) or pomalidomide (POM)...Sixteen (28%) pts received BELA+proteosome inhibitor (PI) (14 BOR, 2 carfilzomib); 30 (52.6%) pts received BELA+immunomodulatory drug (IMiD) (26 POM, 4 lenalidomide (LEN))... Belantamab mafodotin shows significant anti-myeloma activity in early RRMM pts with high rate of daratumumab exposure in a real-world setting with a manageable safety profile."

Clinical • Cardiovascular • Congestive Heart Failure • Febrile Neutropenia • Gastrointestinal Disorder • Heart Failure • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Myocardial Infarction • Neutropenia • Ophthalmology • Thrombocytopenia

Preclinical Evaluation of ?-Glucuronide Linker-Based BCMA Adcs with MMAF, Propbd, and TOP1 Inhibitor Payloads Support Differentiated Clinical Development Strategies (IMS 2026) - "Introduction: Belantamab mafodotin combination therapies have demonstrated the potential of BCMA-targeted antibody-drug conjugates (ADCs) in the multiple myeloma treatment landscape, yet are limited by the prevalence of ocular toxicity. LCB14-2524 (LBG-MMAF), LCB14-2516 (LBG-proPBD), and LCB43-101001 (Novel TOP1i) all demonstrated preclinical profiles supporting further development. LCB14-2524 has been prioritized for first clinical assessment based on the combination of pre-clinical profile and clinical experience with the platform linker-payload (FS-1502/IKS014). LCB14-2516 or LCB43-101001 provide differentiated follow-on opportunities to introduce new payload mechanism into the multiple myeloma treatment landscape."

Preclinical • Hematological Malignancies • Multiple Myeloma • Ophthalmology • TOP1

PFS2 Outcomes in DREAMM-8: Belantamab Mafodotin (Belamaf)-Pomalidomide-Dexamethasone (Bpd) vs Pomalidomide-Bortezomib-Dexamethasone (Pvd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - P3 | " DREAMM-8 (NCT04484623) is a phase 3, randomized, open-label study evaluating BPd vs PVd in pts with RRMM with ≥1 prior line of therapy including lenalidomide (LEN)...Of pts receiving FST (n=149), 21 (14%) received novel therapies (BPd, n=6 [11%]; PVd, n=15 [16%]), including BCMA-targeted bispecific antibodies (bsAbs), non-BCMA bsAbs, CELMoDs, venetoclax, and belamaf... BCMA-directed therapy, BPd, resulted in improved PFS2 outcomes vs PVd, demonstrating sustained clinical benefit beyond initial belamaf therapy. This benefit was seen regardless of prior treatment, with LEN-refractory pts experiencing almost a 3-fold PFS2 benefit, and despite a higher proportion of pts receiving novel therapies as FST in the PVd arm. PFS2 benefit with high use of subsequent anti-CD38 agents supports sequencing of belamaf combinations early in the treatment paradigm prior to anti-CD38 agents."

Clinical • Hematological Malignancies • Multiple Myeloma

Patient Characteristics and Initial Real-World Dosing Experience with Belantamab Mafodotin-Based Combinations for Relapsed/Refractory Multiple Myeloma (IMS 2026) - "The DREAMM-7 and DREAMM-8 studies showed robust efficacy of anti-BCMA antibody-drug conjugate belantamab mafodotin (belamaf) + bortezomib + dexamethasone (BVd) and belamaf + pomalidomide + dexamethasone (BPd) vs SoC triplets for pts with RRMM who had received ≥1 prior line of tx. S imilar to the clinical studies, physicians used extended dosing to improve belamaf tolerability and keep pts on treatment. Real-world belamaf use in earlier lines of tx signifies the unmet need for efficacious tx at first relapse. Funding: GSK (224207)."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Multiple Myeloma

Open-Label, Single-Arm Phase Ib/Ii Study of Immune Combination Therapy with Belantamab Mafodotin and Elotuzumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - P1/2 | "The combination immune therapy of belantamab mafodotin and elotuzumab appears to have an encouraging safety profile and a promising activity in patients with heavily pretreated RRMM, including in those with prior failure of BCMA-targeted T-cell redirection therapy. Funding and Product for this study was provided by GSK NCT05002816 ."

Clinical • Combination therapy • P1/2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Ophthalmology • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Long-Term Outcomes With Sustained Minimal Residual Disease (MRD) Negativity in Belantamab Mafodotin-Treated Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): An Update From DREAMM-8 (IMS 2026) - P3 | "In the phase 3 DREAMM-8 trial (NCT04484623), BCMA-directed antibody-drug conjugate (ADC) belantamab mafodotin plus pomalidomide and dexamethasone (BPd) demonstrated significant progression-free survival (PFS) benefit and higher rates of complete response (CR)–based MRD negativity vs triplet pomalidomide, bortezomib, dexamethasone (PVd) in pts with RRMM and ≥1 prior line of therapy (LOT)... Pts with ≥1 prior LOT including lenalidomide were randomized 1:1 to BPd or PVd... Pts receiving BPd vs PVd were >4 × more likely to achieve sustained MRD negativity, which was associated with improved PFS and PFS2. Within the BPd arm, MRD negative vs positive pts more often had 1 prior LOT, further supporting the use of BPd, a BCMA - directed ADC regimen, in earlier LOTs for RRMM, including in pts with high-risk cytogenetics . Sponsorship: GSK (study ID 207499) Copyright statement"

Clinical • IO biomarker • Minimal residual disease • Residual disease • Hematological Malignancies • Multiple Myeloma

Matching-Adjusted Indirect Treatment Comparison of Teclistamab Monotherapy (Tec) vs Belantamab with Pomalidomide and Dexamethasone (Bpd) for Early-Line Relapsed or Refractory Multiple Myeloma (RRMM) (IMS 2026) - P3 | "In DREAMM-8 (NCT04484623), belantamab mafodotin, a BCMA-directed ADC, plus Pd (BPd) also improved PFS vs PVd in early-line RRMM; 24% were anti-CD38 refractory. Tec monotherapy showed superior PFS benefit and doubled the likelihood of achieving ≥CR, an important indicator of durable responses, vs BPd in pts with early-line RRMM per anchored MAIC. Although MajesTEC-9 included a heavily anti-CD38 refractory population, Tec’s comparative benefit persisted after MAIC adjustment, supporting Tec as a highly effective standard-of-care therapy as early as first relapse, regardless of anti-CD38 exposure/refractory status."

Monotherapy • Hematological Malignancies • Multiple Myeloma

Matching-Adjusted Indirect Comparison (MAIC) of Belantamab Mafodotin, Bortezomib, Dexamethasone (Bvd) vs Carfilzomib, Lenalidomide, Dexamethasone (Krd) in Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - P3 | "Introduction: BVd is approved for RRMM based on superior efficacy vs daratumumab plus bortezomib/dexamethasone in the phase 3 DREAMM-7 trial (NCT04246047). BVd had significantly longer PFS/OS vs KRd when adjusting for differences in key baseline pt characteristics. Response outcomes were similar, though the inherent limitations of MAICs (e.g., population size, trial differences) may have affected these analyses. Prolonged survival benefits may be achieved with BVd over KRd, demonstrating its utility for treatment of pts with 2L+ RRMM."

Hematological Malignancies • Multiple Myeloma

Mass Spectrometry Identifies Actionable Myeloma Relapse Eight Months Before Electrophoretic Detection (IMS 2026) - "First-line therapy commenced with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (Dara-VCD) in July 2024, achieving a complete serological remission, and subsequently continued on daratumumab maintenance. Had this early relapse been recognised in real time, treatment escalation to a multi-class regimen such as belantamab mafodotin, bortezomib, and dexamethasone (Bela-Vd), or consideration of bispecific or CAR-T therapy (requiring disease control and potentially avoiding bridging therapy), could have been pursued earlier, with the aim of achieving a deeper response before the development of end-organ damage. This case demonstrates that mass spectrometry can detect relapse significantly earlier than conventional electrophoretic methods, providing a clinically meaningful window for earlier intervention at low disease burden. Prospective integration of assays such as EXENT™ GAM into routine monitoring pathways may enable more sensitive disease tracking, inform..."

Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Pain • Orthopedics • B2M

Lipid Droplets in Multiple Myeloma: Association with Disease Progression and Therapeutic Resistance (IMS 2026) - "LD levels were determined in MM cell lines, including MM1S and RPMI8226 sensitive and resistant to Belantamab mafodotin (BLMF), OPM2 and KMS11 sensitive and resistant to Bortezomib, and U266 sensitive and resistant to Melphalan. LD accumulation is a distinctive feature of PCs in MM, suggesting the existence of metabolic reprogramming through disease progression, the microenvironment and therapeutic resistance. These results position lipid metabolism, and particularly LDs, as a potential therapeutic target in MM."

Hematological Malignancies • Metabolic Disorders • Monoclonal Gammopathy • Multiple Myeloma • PLIN2

Investigating V?9Vd2 T-Cell Cytotoxicity in Multiple Myeloma in Combination with BCMA Targeting (IMS 2026) - "This study aims to investigate molecular mechanisms associated with the variable response to the combination treatment with the antibody-drug conjugate Belantamab-Mafodotin (Bel-Maf)... These preliminary findings reveal heterogeneous responses to Bel-Maf and Vγ9Vδ2 T-cell-mediated cytotoxicity across MM models. Further studies are required to define the biological factors governing susceptibility to BCMA-targeted and immune-mediated antitumor responses."

Combination therapy • IO biomarker • Hematological Malignancies • Multiple Myeloma • ANXA5 • NCAM1 • NKG2D

Impact of Prior Anti-Bcma Antibody-Drug Conjugate Exposure and High-Risk Cytogenetics on Outcomes with BCMA Bispecifics in Relapsed/Refractory Multiple Myeloma: A Single Centre Real-World Analysis (IMS 2026) - "Median PFS was 9.8 months, with no difference between teclistamab and elranatamab (HR 1.05, p=0.87). Fourteen patients (25%) had prior belantamab mafodotin exposure and all were ADC-refractory before TCE treatment...Prior belantamab exposure did not adversely affect PFS following TCE therapy (HR 1.29, 95%CI 0.61–2.69; p=0.5); 12-month PFS was 48% versus 53% in belantamab-exposed versus non-exposed patients, respectively... In this real-world RRMM cohort with prolonged follow-up, prior anti-BCMA ADC exposure did not impair outcomes of subsequent BCMA-targeting TCE therapy. Conversely, extramedullary disease and cumulative HRCA burden remained associated with inferior outcomes, supporting their continued prognostic relevance in the bispecific antibody era."

ADC • Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Plasmacytoma

High MRD- Rates and Prolonged PFS with Belantamab Mafodotin Plus Daratumumab, Lenalidomide, and Dexamethasone in Transplant Ineligible Newly-Diagnosed Myeloma: Results of the Phase 1/2 Beladrd Study (IMS 2026) - P1/2 | "The study showed rapid, deep responses and high MRD negativity rates. Low frequency of ≥Gr 3 OAEs occurred and resolved rapidly. Similar frequency of OAEs occurred when dosing was guided by haematologist vs ophthalmologist ocular assessment."

P1/2 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Ophthalmology • Transplantation

Extrapolated Progression-Free Survival with Belantamab Mafodotin/Lenalidomide/Dexamethasone (Brd) Exceeds 7 Years in Intermediate-Fit and Frail, Transplant-Ineligible, Newly Diagnosed Multiple Myeloma (IMS 2026) - P1/2 | "Anti-CD38-based regimens (daratumumab + lenalidomide + dexamethasone +/− bortezomib [DRd and DVRd]; isatuximab + VRd [IsaVRd]) are SOC for TI-NDMM based on the MAIA, CEPHEUS, and IMROZ trials. Model-predicted mPFS (based on survival extrapolation) of BRd in TI-NDMM (87.6–110.7 months for 1.9 mg/kg-only cohort and 85.5–110.0 months overall) was longer than the reported mPFS for the triplet (DRd: mPFS 61.9 months at 64.5 months mFU) and comparable to that expected for the quadruplets (DVRd: 96–118 months; IsaVRd: 90 months). All pts were intermediate-fit or frail, highlighting the importance of these results in this population with unmet need. Within the analytical limitations (small sample size, small numbers at risk at later timepoints in Kaplan-Meier analyses, and duration of FU), predicted mPFS in the combined cohorts and the 1.9 mg/kg-only cohort was similar, suggesting potential for high efficacy with BRd for TI-NDMM."

Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Transplantation

DREAMM-15: A Study Assessing the Efficacy and Safety of Extended-Dose Belantamab Mafodotin in Combination with Standard-Of-Care Therapies in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - P2 | "Belamaf (B), bortezomib (V), and dexamethasone (d) [BVd] has also demonstrated statistically significant improvement in overall survival (DREAMM-7) vs an anti-CD38–containing triplet, daratumumab + Vd (DVd)...Notable exclusion criteria include prior exposure to BCMA-targeted therapy and being intolerant/refractory to pomalidomide, bortezomib, or carfilzomib depending on group allocation... N/A"

Clinical • Combination therapy • Hematological Disorders • Hematological Malignancies • Multiple Myeloma

Design of the Phase 2 ALANIS Study: Belantamab Mafodotin in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (Vcd) in Patients with Newly Diagnosed Amyloid Light Chain Amyloidosis (IMS 2026) - P2 | "The ALANIS trial will determine the role of belamaf in the newly diagnosed AL amyloidosis treatment landscape, where new therapies providing deep responses are needed. Funding: GSK. Drug linker technology licensed from Seagen Inc.; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa."

Clinical • Combination therapy • P2 data • Amyloidosis • Cardiovascular • Hematological Disorders • Ophthalmology • Renal Disease

Deep Sustained Response to Belantamab Mafodotin Despite Reversible Grade 4 Ocular Toxicity in Relapsed/Refractory Multiple Myeloma in the Brazilian Public Health System (IMS 2026) - "Belantamab,bortezomib and dexamethasone (Bela-Vd) and achieved a deep and sustained response after only two infusions, despite developing fully reversible grade 4 ocular toxicity. This case highlights the remarkable antitumor activity of belantamab even after limited exposure, including in the setting of relapsed disease. The occurrence of KVA4 represents a clinically significant treatment-limiting complication. Nevertheless, the clinical course observed in this patient reinforces that ocular toxicity may be reversible even in severe cases."

Hematological Malignancies • Multiple Myeloma • Ophthalmology

Belantamab Mafodotin, Pomalidomide, and Dexamethasone (Bpd) Demonstrated Improved Outcomes as Second-Line Therapy vs Pomalidomide, Bortezomib, and Dexamethasone (Pvd) in Patients with Multiple Myeloma (IMS 2026) - P3 | "All patients were lenalidomide exposed and had not received prior BCMA-targeted therapy. BPd as 2L treatment in patients with RRMM demonstrated durable benefits in PFS, DOR, and PFS2, in addition to deep responses. This analysis further supports the use of BPd as early as first relapse. With BCMA-targeted treatments making notable advancements in outcomes for patients with RRMM, belamaf combinations offer both broad accessibility to durable outcomes as well as a patient-centric profile, with extended dosing intervals and outpatient administration."

Clinical • IO biomarker • Hematological Disorders • Hematological Malignancies • Multiple Myeloma

Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated 4-Year Results of the Phase 3 DREAMM-7 Trial (IMS 2026) - P3 | "After >4 years, BVd OS benefits remained superior to DVd. Many patients achieved deep remission and PFS benefit, with a safety profile consistent with the known profile of belamaf. These results, along with the ability for outpatient administration, support BVd as a potential new standard-of-care in RRMM at first relapse or later."

P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma